Logo image of RGEN

REPLIGEN CORP (RGEN) Stock Fundamental Analysis

NASDAQ:RGEN - Nasdaq - US7599161095 - Common Stock - Currency: USD

158.99  -3.68 (-2.26%)

After market: 158.99 0 (0%)

Fundamental Rating

4

RGEN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year RGEN was profitable.
RGEN had a positive operating cash flow in the past year.
RGEN had positive earnings in 4 of the past 5 years.
RGEN had a positive operating cash flow in 4 of the past 5 years.
RGEN Yearly Net Income VS EBIT VS OCF VS FCFRGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

1.2 Ratios

RGEN has a Return On Assets of -0.53%. This is in the better half of the industry: RGEN outperforms 68.42% of its industry peers.
RGEN's Return On Equity of -0.75% is fine compared to the rest of the industry. RGEN outperforms 70.18% of its industry peers.
RGEN has a better Return On Invested Capital (0.49%) than 63.16% of its industry peers.
The Average Return On Invested Capital over the past 3 years for RGEN is below the industry average of 9.60%.
The 3 year average ROIC (5.35%) for RGEN is well above the current ROIC(0.49%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -0.53%
ROE -0.75%
ROIC 0.49%
ROA(3y)4.76%
ROA(5y)3.79%
ROE(3y)6.39%
ROE(5y)5.02%
ROIC(3y)5.35%
ROIC(5y)4.31%
RGEN Yearly ROA, ROE, ROICRGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2 4 6 8 10

1.3 Margins

RGEN's Profit Margin has declined in the last couple of years.
The Operating Margin of RGEN (2.29%) is better than 63.16% of its industry peers.
RGEN's Operating Margin has declined in the last couple of years.
The Gross Margin of RGEN (50.28%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of RGEN has declined.
Industry RankSector Rank
OM 2.29%
PM (TTM) N/A
GM 50.28%
OM growth 3Y-12.31%
OM growth 5Y-1.83%
PM growth 3Y-26.44%
PM growth 5Y-5.32%
GM growth 3Y-4.81%
GM growth 5Y-2.29%
RGEN Yearly Profit, Operating, Gross MarginsRGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30 40 50

More info and screens

7

2. Health

2.1 Basic Checks

RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
RGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGEN Yearly Shares OutstandingRGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
RGEN Yearly Total Debt VS Total AssetsRGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 7.66 indicates that RGEN is not in any danger for bankruptcy at the moment.
RGEN has a better Altman-Z score (7.66) than 91.23% of its industry peers.
RGEN has a debt to FCF ratio of 3.97. This is a good value and a sign of high solvency as RGEN would need 3.97 years to pay back of all of its debts.
RGEN has a Debt to FCF ratio of 3.97. This is in the better half of the industry: RGEN outperforms 77.19% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.26, RGEN perfoms like the industry average, outperforming 54.39% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 3.97
Altman-Z 7.66
ROIC/WACC0.04
WACC11.04%
RGEN Yearly LT Debt VS Equity VS FCFRGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.3 Liquidity

RGEN has a Current Ratio of 10.44. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a better Current ratio (10.44) than 92.98% of its industry peers.
A Quick Ratio of 8.76 indicates that RGEN has no problem at all paying its short term obligations.
RGEN has a better Quick ratio (8.76) than 87.72% of its industry peers.
Industry RankSector Rank
Current Ratio 10.44
Quick Ratio 8.76
RGEN Yearly Current Assets VS Current LiabilitesRGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for RGEN have decreased strongly by -14.45% in the last year.
Measured over the past 5 years, RGEN shows a small growth in Earnings Per Share. The EPS has been growing by 7.11% on average per year.
EPS 1Y (TTM)-14.45%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.58%

3.2 Future

The Earnings Per Share is expected to grow by 20.26% on average over the next years. This is a very strong growth
Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 17.34% on average per year.
EPS Next Y18.8%
EPS Next 2Y23.59%
EPS Next 3Y29.21%
EPS Next 5Y20.26%
Revenue Next Year9.57%
Revenue Next 2Y12.35%
Revenue Next 3Y14.27%
Revenue Next 5Y17.34%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
RGEN Yearly Revenue VS EstimatesRGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
RGEN Yearly EPS VS EstimatesRGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1 2 3 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 107.43, which means the current valuation is very expensive for RGEN.
RGEN's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (29.63), we can say RGEN is valued expensively.
A Price/Forward Earnings ratio of 90.43 indicates a quite expensive valuation of RGEN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN is on the same level as its industry peers.
RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 22.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 107.43
Fwd PE 90.43
RGEN Price Earnings VS Forward Price EarningsRGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN indicates a somewhat cheap valuation: RGEN is cheaper than 61.40% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 67.88
EV/EBITDA 102.72
RGEN Per share dataRGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 29.21% in the coming years.
PEG (NY)5.71
PEG (5Y)15.12
EPS Next 2Y23.59%
EPS Next 3Y29.21%

More info and screens

0

5. Dividend

5.1 Amount

RGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REPLIGEN CORP

NASDAQ:RGEN (2/21/2025, 8:00:01 PM)

After market: 158.99 0 (0%)

158.99

-3.68 (-2.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)04-29 2025-04-29/bmo
Inst Owners103.1%
Inst Owner Change1.72%
Ins Owners0.5%
Ins Owner Change1.63%
Market Cap8.91B
Analysts80
Price Target193.44 (21.67%)
Short Float %6.31%
Short Ratio6.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.55%
Min EPS beat(2)-0.8%
Max EPS beat(2)25.89%
EPS beat(4)1
Avg EPS beat(4)3.87%
Min EPS beat(4)-9%
Max EPS beat(4)25.89%
EPS beat(8)5
Avg EPS beat(8)10.39%
EPS beat(12)9
Avg EPS beat(12)13.86%
EPS beat(16)13
Avg EPS beat(16)22.42%
Revenue beat(2)0
Avg Revenue beat(2)-1.46%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)-0.93%
Revenue beat(4)0
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-1.99%
Max Revenue beat(4)-0.93%
Revenue beat(8)0
Avg Revenue beat(8)-1.92%
Revenue beat(12)4
Avg Revenue beat(12)0.49%
Revenue beat(16)8
Avg Revenue beat(16)3.52%
PT rev (1m)-0.66%
PT rev (3m)-0.88%
EPS NQ rev (1m)-0.97%
EPS NQ rev (3m)-10.61%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)7.48%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-1.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.81%
Valuation
Industry RankSector Rank
PE 107.43
Fwd PE 90.43
P/S 11.51
P/FCF 67.88
P/OCF 53.91
P/B 4.42
P/tB 13.74
EV/EBITDA 102.72
EPS(TTM)1.48
EY0.93%
EPS(NY)1.76
Fwd EY1.11%
FCF(TTM)2.34
FCFY1.47%
OCF(TTM)2.95
OCFY1.85%
SpS13.81
BVpS35.99
TBVpS11.57
PEG (NY)5.71
PEG (5Y)15.12
Profitability
Industry RankSector Rank
ROA -0.53%
ROE -0.75%
ROCE 0.65%
ROIC 0.49%
ROICexc 0.68%
ROICexgc 2.32%
OM 2.29%
PM (TTM) N/A
GM 50.28%
FCFM 16.96%
ROA(3y)4.76%
ROA(5y)3.79%
ROE(3y)6.39%
ROE(5y)5.02%
ROIC(3y)5.35%
ROIC(5y)4.31%
ROICexc(3y)7.61%
ROICexc(5y)6.5%
ROICexgc(3y)45.54%
ROICexgc(5y)N/A
ROCE(3y)7.15%
ROCE(5y)5.76%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-18.97%
ROICexc growth 5Y-6.69%
OM growth 3Y-12.31%
OM growth 5Y-1.83%
PM growth 3Y-26.44%
PM growth 5Y-5.32%
GM growth 3Y-4.81%
GM growth 5Y-2.29%
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 3.97
Debt/EBITDA 6.05
Cap/Depr 49.64%
Cap/Sales 4.39%
Interest Coverage 250
Cash Conversion 191.74%
Profit Quality N/A
Current Ratio 10.44
Quick Ratio 8.76
Altman-Z 7.66
F-Score5
WACC11.04%
ROIC/WACC0.04
Cap/Depr(3y)138.69%
Cap/Depr(5y)124.83%
Cap/Sales(3y)9.25%
Cap/Sales(5y)8.7%
Profit Quality(3y)87.48%
Profit Quality(5y)105.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-14.45%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%33.33%
EPS Next Y18.8%
EPS Next 2Y23.59%
EPS Next 3Y29.21%
EPS Next 5Y20.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.58%
Revenue Next Year9.57%
Revenue Next 2Y12.35%
Revenue Next 3Y14.27%
Revenue Next 5Y17.34%
EBIT growth 1Y-68.36%
EBIT growth 3Y5.55%
EBIT growth 5Y24.59%
EBIT Next Year15.26%
EBIT Next 3Y21.56%
EBIT Next 5Y25.7%
FCF growth 1Y120.94%
FCF growth 3Y27.33%
FCF growth 5Y30.23%
OCF growth 1Y3.4%
OCF growth 3Y22.09%
OCF growth 5Y28.28%